Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium Avium Infection

Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.01761-09
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Microbiology

Related search

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium Avium

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2010English

A Yong Boy With Disseminated Mycobacterium Avium Complex Infection

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2019English

Low-Dose Dexamethasone as Adjunctive Therapy for Disseminated Mycobacterium Avium Complex Infections in AIDS Patients.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1994English

Infection Due to Mycobacterium Avium

BMJ
1963English

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

Clinical Cancer Research
Cancer ResearchOncology
2014English

Pharmacokinetics and Pharmacodynamics of Two Multiple-Dose Piperacillin-Tazobactam Regimens.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1997English

Rational Choice of Antibiotics and Media for Mycobacterium Avium Complex Drug Susceptibility Testing

Frontiers in Microbiology
Microbiology
2020English

Unusual Presentation of Canine Mycobacterium Avium Infection

Veterinary Record
MedicineVeterinary
2019English

Identification of Mycobacterium Avium Complex in Sarcoidosis.

Journal of Clinical Microbiology
Microbiology
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy